|
1
|
Leyland-Jones B, Semiglazov V, Pawlicki M,
Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell
D, Baselga J, et al: Maintaining normal hemoglobin levels with
epoetin alfa in mainly nonanemic patients with metastatic breast
cancer receiving first-line chemotherapy: A survival study. J Clin
Oncol. 23:5960–5972. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Henke M, Laszig R, Rube C, Schäfer U,
Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and
Frommhold H: Erythropoietin to treat head and neck cancer patients
with anaemia undergoing radiotherapy: Randomised, double-blind,
placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watowich SS: The erythropoietin receptor:
Molecular structure and hematopoietic signaling pathways. J
Investig Med. 59:1067–1072. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Debeljak N, Solar P and Sytkowski AJ:
Erythropoietin and cancer: The unintended consequences of anemia
correction. Front Immunol. 5:5632014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arcasoy MO, Jiang X and Haroon ZA:
Expression of erythropoietin receptor splice variants in human
cancer. Biochem Biophys Res Commun. 307:999–1007. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Osterborg A, Aapro M, Cornes P, Haselbeck
A, Hayward CR and Jelkmann W: Preclinical studies of erythropoietin
receptor expression in tumour cells: Impact on clinical use of
erythropoietic proteins to correct cancer-related anaemia. Eur J
Cancer. 43:510–519. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Swift S, Ellison AR, Kassner P, McCaffery
I, Rossi J, Sinclair AM, Begley CG and Elliott S: Absence of
functional EpoR expression in human tumor cell lines. Blood.
115:4254–4263. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marupudi NI, Han JE, Li KW, Renard VM,
Tyler BM and Brem H: Paclitaxel: A review of adverse toxicities and
novel delivery strategies. Expert Opin Drug Saf. 6:609–621. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orr JW Jr: What constitutes the ‘optimal’
treatment environment of women with gynecologic cancer? Gynecol
Oncol. 89:1–3. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Larsson AM, Jirstrom K, Fredlund E,
Nilsson S, Rydén L, Landberg G and Påhlman S: Erythropoietin
receptor expression and correlation to tamoxifen response and
prognosis in breast cancer. Clin Cancer Res. 15:5552–5559. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Volgger B, Kurz K, Zoschg K, Theurl I,
Ciresa-König A, Marth C and Weiss G: Importance of erythropoetin
receptor expression in tumour tissue for the clinical course of
breast cancer. Anticancer Res. 30:3721–3726. 2010.PubMed/NCBI
|
|
12
|
Reinbothe S, Larsson AM, Vaapil M, Wigerup
C, Sun J, Jögi A, Neumann D, Rönnstrand L and Påhlman S:
EPO-independent functional EPO receptor in breast cancer enhances
estrogen receptor activity and promotes cell proliferation. Biochem
Biophys Res Commun. 445:163–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ilkovičová L, Trošt N, Szentpéteriová E,
Solár P, Komel R and Debeljak N: Overexpression of the
erythropoietin receptor in RAMA 37 breast cancer cells alters cell
growth and sensitivity to tamoxifen. Int J Oncol. 51:737–746. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niyazi M, Niyazi I and Belka C: Counting
colonies of clonogenic assays by using densitometric software.
Radiat Oncol. 2:42007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aapro M, Leonard RC, Barnadas A, Marangolo
M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma
L, et al: Effect of once-weekly epoetin beta on survival in
patients with metastatic breast cancer receiving anthracycline-
and/or taxane-based chemotherapy: Results of the breast
cancer-anemia and the value of erythropoietin (BRAVE) study. J Clin
Oncol. 26:592–598. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aapro M, Gascon P, Patel K, Rodgers GM,
Fung S, Arantes LH Jr and Wish J: Erythropoiesis-stimulating agents
in the management of anemia in chronic kidney disease or cancer: A
historical perspective. Front Pharmacol. 9:14982019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leyland-Jones B, Bondarenko I, Nemsadze G,
Smirnov V, Litvin I, Kokhreidze I, Abshilava L, Janjalia M, Li R,
Lakshmaiah KC, et al: A randomized, open-label, multicenter, phase
III study of epoetin alfa versus best standard of care in anemic
patients with metastatic breast cancer receiving standard
chemotherapy. J Clin Oncol. 34:1197–1207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagarkar R, Gascón P, Šmakal M, Syrigos K,
Barrios C, Cárdenas Sánchez J, Zhang L, Tomita D, Park J and De
Oliveira Brandao C: A double-blind, randomized, placebo-controlled
phase 3 noninferiority study of darbepoetin alfa for anemia in
advanced NSCLC. MA02.05. J Thorac Oncol. 13 (Suppl):S3592018.
View Article : Google Scholar
|
|
19
|
Miller CP, Lowe KA, Valliant-Saunders K,
Kaiser JF, Mattern D, Urban N, Henke M and Blau CA: Evaluating
erythropoietin-associated tumor progression using archival tissues
from a phase III clinical trial. Stem Cells. 27:2353–2361. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hadland BK and Longmore GD:
Erythroid-stimulating agents in cancer therapy: Potential dangers
and biologic mechanisms. J Clin Oncol. 27:4217–4226. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jelkmann W, Bohlius J, Hallek M and
Sytkowski AJ: The erythropoietin receptor in normal and cancer
tissues. Crit Rev Oncol Hematol. 67:39–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elliott S, Busse L, Bass MB, Lu H, Sarosi
I, Sinclair AM, Spahr C, Um M, Van G and Begley CG: Anti-Epo
receptor antibodies do not predict Epo receptor expression. Blood.
107:1892–1895. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Elliott S, Swift S, Busse L, Scully S, Van
G, Rossi J and Johnson C: Epo receptors are not detectable in
primary human tumor tissue samples. PLoS One. 8:e680832013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z,
Wang H, McLendon RE, Hjelmeland AB and Rich JN: Erythropoietin
receptor signaling through STAT3 is required for glioma stem cell
maintenance. Genes Cancer. 1:50–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu
X and Acs G: RNA interference-mediated inhibition of erythropoietin
receptor expression suppresses tumor growth and invasiveness in
A2780 human ovarian carcinoma cells. Am J Pathol. 174:1504–1514.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ueda F, Tago K, Tamura H and
Funakoshi-Tago M: Three tyrosine residues in the erythropoietin
receptor are essential for janus kinase 2 V617F mutant-induced
tumorigenesis. J Biol Chem. 292:1826–1846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Todaro M, Turdo A, Bartucci M, Iovino F,
Dattilo R, Biffoni M, Stassi G, Federici G, De Maria R and Zeuner
A: Erythropoietin activates cell survival pathways in breast cancer
stem-like cells to protect them from chemotherapy. Cancer Res.
73:6393–6400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumar SM, Zhang G, Bastian BC, Arcasoy MO,
Karande P, Pushparajan A, Acs G and Xu X: Erythropoietin receptor
contributes to melanoma cell survival in vivo. Oncogene.
31:1649–1660. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ
and Feldman L: An erythropoietin autocrine/paracrine axis modulates
the growth and survival of human prostate cancer cells. Mol Cancer
Res. 7:1150–1157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi Z, Hodges VM, Dunlop EA, Percy MJ,
Maxwell AP, El-Tanani M and Lappin TR: Erythropoietin-induced
activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways
promotes malignant cell behavior in a modified breast cancer cell
line. Mol Cancer Res. 8:615–626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu G, Qin XQ, Guo JJ, Li TY and Chen JH:
AKT/ERK activation is associated with gastric cancer cell
resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458.
2014.PubMed/NCBI
|
|
32
|
Chun E and Lee KY: Bcl-2 and Bcl-xL are
important for the induction of paclitaxel resistance in human
hepatocellular carcinoma cells. Biochem Biophys Res Commun.
315:771–779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Solar P, Feldman L, Jeong JY, Busingye JR
and Sytkowski AJ: Erythropoietin treatment of human ovarian cancer
cells results in enhanced signaling and a paclitaxel-resistant
phenotype. Int J Cancer. 122:281–288. 2008. View Article : Google Scholar : PubMed/NCBI
|
